Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial

@article{Queirolo1999AdoptiveIW,
  title={Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial},
  author={P. J. Queirolo and M. Cristina Ponte and M Gipponi and Ferdinando Cafiero and Alberto Peressini and Claudia Semino and Gabriella Pietra and Rita Lionetto and Stefania Vecchio and Iole Ribizzi and Giovanni Melioli and Mario Roberto Sertoli},
  journal={Annals of Surgical Oncology},
  year={1999},
  volume={6},
  pages={272-278}
}
Background: On the basis of our previous experience, we designed this study to determine the activity and toxicity of outpatient treatment with autologous tumor-infiltrating lymphocytes (TIL) together with intermediate-dose recombinant interleukin-2 (rIL-2) and low-dose recombinant interferon alfa-2a (rIFN-α2a), for patients with metastatic melanoma… CONTINUE READING